Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Relmada Therapeutics CMO Raj S. Pruthi Purchases 55,000 Shares In Open Market On August 29, 2025

Author: Benzinga Newsdesk | September 02, 2025 10:40am

On August 29, 2025, Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, Inc. (the "Company"), purchased in open market transactions 55,000 shares of the Company's common stock, $0.001 par value per share. 

 

Posted In: RLMD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist